A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis

Infection and Immunity

Volumn 80, Issue 1, 2012, Pages 206-214

  Zhang, Yue ^a   Mena, Patricio ^a   Romanov, Galina ^a   Lin, Jr Shiuan ^b   Smiley, Stephen T ^b   Bliska, James B ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; EPITOPE; LYMPHOCYTE ANTIGEN; YERSINIA OUTER PROTEIN E; BACTERIAL VACCINE; IMMUNOLOGICAL ADJUVANT; OUTER MEMBRANE PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; YOPE PROTEIN, YERSINIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; YERSINIA PSEUDOTUBERCULOSIS; YERSINIA PSEUDOTUBERCULOSIS INFECTION; ANIMAL; C57BL MOUSE; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MORTALITY; SPLEEN; SURVIVAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHOLERA TOXIN; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED C57BL; SPLEEN; SURVIVAL ANALYSIS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; YERSINIA PSEUDOTUBERCULOSIS; YERSINIA PSEUDOTUBERCULOSIS INFECTIONS;

EID: 84863239834     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05971-11     Document Type: Article

References (67)

1. Achtman M, et al. 1999. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl. Acad. Sci. U. S. A. 96:14043-14048.
2. Aepfelbacher M, Roppenser B, Hentschke M, Ruckdeschel K. 2011. Activity modulation of the bacterial Rho GAP YopE: an inspiration for the investigation of mammalian Rho GAPs. Eur. J. Cell Biol. 90:951-954.
3. Aili M, et al. 2008. Regulation of Yersinia Yop-effector delivery by translocated YopE. Int. J. Med. Microbiol. 298:183-192.
4. Aili M, Isaksson EL, Hallberg B, Wolf-Watz H, Rosqvist R. 2006. Functional analysis of the YopE GTPase-activating protein (GAP) activity of Yersinia pseudotuberculosis. Cell. Microbiol. 8:1020 -1033.
5. Alto NM. 2008. Mimicking small G-proteins: an emerging theme from the bacterial virulence arsenal. Cell. Microbiol. 10:566 -575.
6. Andor A, et al. 2001. YopE of Yersinia, a GAP for Rho GTPases, selectively modulates Rac-dependent actin structures in endothelial cells. Cell. Microbiol. 3:301-310.
7. Autenrieth IB, Heesemann J. 1992. In vivo neutralization of tumor necrosis factor alpha and interferon-gamma abrogates resistance to Yersinia enterocolitica in mice. Med. Microbiol. Immunol. 181:333-338.
8. Autenrieth IB, Tingle A, Reske-Kunz A, Heesemann J. 1992. T lymphocytes mediate protection against Yersinia enterocolitica in mice: characterization of murine T-cell clones specific for Y. enterocolitica. Infect. Immun. 60:1140 -1149.
9. Autenrieth SE, Autenrieth IB. 2008. Yersinia enterocolitica: subversion of adaptive immunity and implications for vaccine development. Int. J. Med. Microbiol. 298:69 -77.
10. Bergman MA, Loomis WP, Mecsas J, Starnbach MN, Isberg RR. 2009. CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells. PLoS Pathog. 5:e1000573.
11. Black DS, Bliska JB. 2000. The RhoGAP activity of the Yersinia pseudotuberculosis cytotoxin YopE is required for antiphagocytic function and virulence. Mol. Microbiol. 37:515-527.
12. Blisnick T, Ave P, Huerre M, Carniel E, Demeure CE. 2008. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect. Immun. 76:3808 -3816.
13. Blocker AJ, et al. 2008. What's the point of the type III secretion system needle? Proc. Natl. Acad. Sci. U. S. A. 105:6507- 6513.
14. Broberg CA, Orth K. 2010. Tipping the balance by manipulating posttranslational modifications. Curr. Opin. Microbiol. 13:34-40.
15. Brodsky IE, Medzhitov R. 2008. Reduced secretion of YopJ by Yersinia limits in vivo cell death but enhances bacterial virulence. PLoS Pathog. 4:e1000067.
16. Brodsky IE, et al. 2010. A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. Cell Host Microbe 7:376 -387.
17. Bulgin R, et al. 2010. Bacterial guanine nucleotide exchange factors SopElike and WxxxE effectors. Infect. Immun. 78:1417-1425.
18. Cornelis GR. 2006. The type III secretion injectisome. Nat. Rev. Microbiol. 4:811- 825.
19. Cornelis GR, et al. 1998. The virulence plasmid of Yersinia, an antihost genome. Microbiol. Mol. Biol. Rev. 62:1315-1352.
20. Cornelius C, Quenee L, Anderson D, Schneewind O. 2007. Protective immunity against plague. Adv. Exp. Med. Biol. 603:415- 424.
21. Deane JE, Abrusci P, Johnson S, Lea SM. 2010. Timing is everything: the regulation of type III secretion. Cell. Mol. Life Sci. 67:1065-1075.
22. Enninga J, Rosenshine I. 2009. Imaging the assembly, structure and activity of type III secretion systems. Cell. Microbiol. 11:1462-1470.
23. Falgarone G, Blanchard HS, Virecoulon F, Simonet M, Breban M. 1999. Coordinate involvement of invasin and Yop proteins in a Yersinia pseudotuberculosis-specific class I-restricted cytotoxic T cell-mediated response. J. Immunol. 162:2875-2883.
24. Galan JE. 2009. Common themes in the design and function of bacterial effectors. Cell Host Microbe 5:571-579.
25. Galan JE, Wolf-Watz H. 2006. Protein delivery into eukaryotic cells by type III secretion machines. Nature 444:567-573.
26. Gaus K, et al. 2011. Destabilization of YopE by the ubiquitin-proteasome pathway fine-tunes Yop delivery into host cells and facilitates systemic spread of Yersinia enterocolitica in host lymphoid tissue. Infect. Immun. 79:1166 -1175.
27. Isaksson EL, et al. 2009. The membrane localization domain is required for intracellular localization and autoregulation of YopE in Yersinia pseudotuberculosis. Infect. Immun. 77:4740-4749.
28. Koberle M, et al. 2009. Yersinia enterocolitica targets cells of the innate and adaptive immune system by injection of Yops in a mouse infection model. PLoS Pathog. 5:e1000551.
29. Krall R, Zhang Y, Barbieri JT. 2004. Intracellular membrane localization of Pseudomonas ExoS and Yersinia YopE in mammalian cells. J. Biol. Chem. 279:2747-2753.
30. Leibiger R, Niedung K, Geginat G, Heesemann J, Trulzsch K. 2008. Yersinia enterocolitica Yop mutants as oral live carrier vaccines. Vaccine 26:6664-6670.
31. Lin JS, Szaba FM, Kummer LW, Chromy BA, Smiley ST. 2011. Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague. J. Immunol. 187:897-904.
32. Logsdon LK, Mecsas J. 2003. Requirement of the Yersinia pseudotuberculosis effectors YopH and YopE in colonization and persistence in intestinal and lymph tissues. Infect. Immun. 71:4595- 4607.
33. Marlovits TC, Stebbins CE. 2010. Type III secretion systems shape up as they ship out. Curr. Opin. Microbiol. 13:47-52.
34. Mattei PJ, et al. 2011. Membrane targeting and pore formation by the type III secretion system translocon. FEBS J. 278:414-426.
35. McPhee JB, Mena P, Bliska JB. 2010. Delineation of regions of the Yersinia YopM protein required for interaction with the RSK1 and PRK2 host kinases and their requirement for interleukin-10 production and virulence. Infect. Immun. 78:3529 -3539.
36. Mejia E, Bliska JB, Viboud GI. 2008. Yersinia controls type III effector delivery into host cells by modulating Rho activity. PLoS Pathog. 4:e3.
37. Mueller CA, Broz P, Cornelis GR. 2008. The type III secretion system tip complex and translocon. Mol. Microbiol. 68:1085-1095.
38. Parent MA, et al. 2005. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun. 73:7304 -7310.
39. Perry RD, Fetherston JD. 1997. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10:35- 66.
40. Philipovskiy AV, Smiley ST. 2007. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect. Immun. 75:878-885.
41. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:834 - 841.
42. Russmann H. 2004. Inverted pathogenicity: the use of pathogen-specific molecular mechanisms for prevention or therapy of disease. Int. J. Med. Microbiol. 293:565-569.
43. Russmann H, et al. 2003. Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction. Infect. Immun. 71:3463-3472.
44. Russmann H, et al. 2010. Alternative endogenous protein processing via an autophagy-dependent pathway compensates for Yersinia-mediated inhibition of endosomal major histocompatibility complex class II antigen presentation. Infect. Immun. 78:5138 -5150.
45. Russmann H, et al. 2000. Yersinia enterocolitica-mediated translocation of defined fusion proteins to the cytosol of mammalian cells results in peptide-specific MHC class I-restricted antigen presentation. Eur. J. Immunol. 30:1375-1384.
46. Sato H, Frank DW. 2011. Multi-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other Gram-negative bacteria. Front. Microbiol. 2:142.
47. Simonet M, Berche P, Mazigh D, Veron M. 1985. Protection against Yersinia infection induced by non-virulence-plasmid-encoded antigens. J. Med. Microbiol. 20:225-231.
48. Smiley ST. 2008. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines 7:209 -221.
49. Songsungthong W, Higgins MC, Rolan HG, Murphy JL, Mecsas J. 2010. ROS-inhibitory activity of YopE is required for full virulence of Yersinia in mice. Cell. Microbiol. 12:988 -1001.
50. Starnbach MN, Bevan MJ. 1994. Cells infected with Yersinia present an epitope to class I MHC-restricted CTL. J. Immunol. 153:1603-1612.
51. 2+ in Yersinia pestis include structural genes for outer membrane proteins. Infect. Immun. 51:445- 454.
52. - Yersinia pestis in BALB/c mice. Infect. Immun. 57:1200 -1210.
53. Szaba FM, et al. 2009. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect. Immun. 77:4295- 4304.
54. Taylor VL, Titball RW, Oyston PC. 2005. Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague. Microbiology 151:1919 -1926.
55. Titball RW, Williamson ED. 2001. Vaccination against bubonic and pneumonic plague. Vaccine 19:4175- 4184.
56. Trulzsch K, et al. 2005. Yersinia outer protein P inhibits CD8 T cell priming in the mouse infection model. J. Immunol. 174:4244-4251.
57. Trulzsch K, Sporleder T, Igwe EI, Russmann H, Heesemann J. 2004. Contribution of the major secreted Yops of Yersinia enterocolitica O:8 to pathogenicity in the mouse infection model. Infect. Immun. 72:5227-5234.
58. Trulzsch K, Sporleder T, Leibiger R, Russmann H, Heesemann J. 2008. Yersinia as oral live carrier vaccine: influence of Yersinia outer proteins (Yops) on the T-cell response. Int. J. Med. Microbiol. 298:59-67.
59. Viboud GI, Bliska JB. 2005. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu. Rev. Microbiol. 59:69-89.
60. Von Pawel-Rammingen U, et al. 2000. GAP activity of the Yersinia YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. Mol. Microbiol. 36:737-748.
61. + T cell responses by Yersinia vaccine carrier strains. Vaccine 23:4984-4998.
62. Worrall LJ, Lameignere E, Strynadka NC. 2011. Structural overview of the bacterial injectisome. Curr. Opin. Microbiol. 14:3- 8.
63. Wren BW. 2003. The yersiniae-a model genus to study the rapid evolution of bacterial pathogens. Nat. Rev. Microbiol. 1:55- 64.
64. Zauberman A, et al. 2009. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS One 4:e5938.
65. Zhang Y, Barbieri JT. 2005. A leucine-rich motif targets Pseudomonas aeruginosa ExoS within mammalian cells. Infect. Immun. 73:7938 -7945.
66. Zhang Y, Bliska JB. 2010. YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection. Infect. Immun. 78:2329 -2341.
67. Zhang Y, Murtha J, Roberts MA, Siegel RM, Bliska JB. 2008. Type III secretion decreases bacterial and host survival following phagocytosis of Yersinia pseudotuberculosis by macrophages. Infect. Immun. 76:4299-4310.